Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471849 | 0.85 | PTGS2 (0.51) | BRD4PTGS2PTGS1POLBTDP1 | |
| SCHEMBL2472639 | 0.84 | PTGS2 (0.44) | BRD4PTGS2PTGS1NR3C2GABRA5 | |
| SCHEMBL2471619 | 0.83 | PTGS2 (0.43) | PTGS2PTGS1POLBTDP1L3MBTL1 | |
| SCHEMBL2471848 | 0.80 | PTGS2 (0.61) | BRD4PTGS2PTGS1TDP1L3MBTL1 | |
| SCHEMBL2470865 | 0.79 | PTGS1 (0.44) | BRD4PTGS2PTGS1TDP1L3MBTL1 | |
| SCHEMBL2468922 | 0.78 | PTGS1 (0.47) | PTGS2PTGS1TDP1L3MBTL1GABRA5 | |
| SCHEMBL4970453 | 0.76 | POLB (0.39) | PAX8BRD4PTGS2PTGS1POLB | |
| SCHEMBL2471686 | 0.72 | PAX8 (0.40) | PAX8BRD4PTGS2PTGS1POLB | |
| SCHEMBL6171538 | 0.70 | PTGS2 (0.74) | PAX8PTGS2PTGS1 | |
| SCHEMBL6731919 | 0.70 | PTGS2 (0.55) | PAX8PTGS2PTGS1L3MBTL1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-1968973-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007074078-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | PAX8 4088/4885BRD4 677/4885PTGS2 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.